Clinical Trial Update: Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating Eleclazine (GS-6615) for improving exercise capacity in symptomatic hypertrophic cardiomyopathy was terminated with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• Eleclazine (Eleclazine)

Snippet

Sponsor: Gilead Sciences | Conditions: Hypertrophic Cardiomyopathy | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2018-03-22